keyword
MENU ▼
Read by QxMD icon Read
search

Gleason

keyword
https://www.readbyqxmd.com/read/28817220/klk14-interactions-with-hai-1-and-hai-2-serine-protease-inhibitors-a-molecular-dynamics-and-relative-free-energy-calculations-study
#1
Christian Solís-Calero, Hernandes F Carvalho
Kallikrein 14 (KLK14) is a serine protease linked to several pathologies including prostate cancer and positively correlates with Gleason score. Though KLK14 functioning in cancer is poorly understood, it has been implicated in HGF/Met signaling, given that KLK14 proteolytically inhibits HGF activator-inhibitor 1 (HAI-1), which strongly inhibits pro-HGF activators, thereby contributing to tumor progression. In this work, KLK14 binding to either hepatocyte growth factor activator inhibitor type-1 (HAI-1) or type-2 (HAI-2) was essayed using homology modeling, molecular dynamic simulations and free-energy calculations through MM/PBSA and MM/GBSA...
August 17, 2017: Cell Biology International
https://www.readbyqxmd.com/read/28816284/-predictive-factor-analysis-of-time-to-progression-of-castration-resistant-prostate-cancer-after-androgen-deprivation-therapy
#2
G J Ji, C Huang, G Song, X S Li, Y Song, L Q Zhou
OBJECTIVE: To explore risk factors including prostate-specific antigen (PSA) kinetics for the prediction of castration-resistant prostate cancer (CRPC), and to build a practical model for predicting the progression to CRPC after androgen deprivation therapy (ADT) so as to facilitate clinicians in decision-making for prostate cancer patients receiving ADT. METHODS: A total of 185 patients with prostate cancer who had received ADT as the primary therapy in Department of Urology of Peking University First Hospital from 2003 to 2014 were enrolled retrospectively...
August 18, 2017: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
https://www.readbyqxmd.com/read/28816169/long-term-results-of-a-randomized-trial-comparing-iridium-implant-plus-external-beam-radiation-therapy-with-external-beam-radiation-therapy-alone-in-node-negative-locally-advanced-cancer-of-the-prostate
#3
Ian S Dayes, Sameer Parpia, Jaclyn Gilbert, Jim A Julian, Ian R Davis, Mark N Levine, Jinka Sathya
PURPOSE: To determine the impact on long-term survival from the addition of brachytherapy to external beam radiation therapy (EBRT) in patients with prostate cancer. METHODS AND MATERIALS: Between 1992 and 1997, 104 men with cT2-3, surgically staged node-negative prostate cancer were randomized to receive either EBRT (40 Gy/20 fractions) with iridium implant (35 Gy/48 hours) or EBRT alone (66 Gy/33 fractions) to the prostate. According to T stage, Gleason score, and prostate-specific antigen level, 60% of patients had high-risk disease...
September 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28816074/prostate-specific-antigen-after-salvage-radiotherapy-for-postprostatectomy-biochemical-recurrence-predicts-long-term-outcome-including-overall-survival
#4
Detlef Bartkowiak, Reinhard Thamm, Dirk Bottke, Alessandra Siegmann, Dirk Böhmer, Volker Budach, Thomas Wiegel
BACKGROUND: For patients with recurrent prostate cancer after radical prostatectomy (RP), salvage radiotherapy (SRT) is a second chance of cure. However, depending on risk factors, 40-70% of the patients experience further progression. With a focus on the pre- and post-SRT serum level of the prostate-specific antigen (PSA), we assessed the determinants of the long-term outcome after SRT. PATIENT AND METHODS: Between 1997 and 2011, 464 patients received 3D-conformal SRT with median 66...
August 17, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28812020/pretreatment-serum-cystatin-c-levels-predict-renal-function-but-not-tumor-characteristics-in-patients-with-prostate-neoplasia
#5
Feilong Yang, Dawei Li, Yu Di, Yongzhen Zhang, Yuanwei Zang, Juchao Ren, Lei Yan, Zunlin Zhou, Hainan Liu, Zhonghua Xu
To evaluate the role of Cystatin C (Cys-C) in tumorigenesis and progression of prostate cancer (PCa), we retrospectively collected the clinical information from the records of 492 benign prostatic hyperplasia (BPH), 48 prostatic intraepithelial neoplasia (PIN), and 173 PCa patients, whose disease was newly diagnosed and histologically confirmed. Pretreatment serum Cys-C levels were compared across the various groups and then analyzed to identify relationships, if any, with clinical and pathological characteristics of the PCa patient group...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28811991/systematic-review-of-the-outcomes-of-surgical-treatment-of-prostate-metastases-to-the-spine
#6
REVIEW
Michelle J Clarke, Camilo A Molina, Daryl R Fourney, Charles G Fisher, Ziya L Gokaslan, Meic H Schmidt, Laurence D Rhines, Michael G Fehlings, Ilya Laufer, Shreyaskumar R Patel, Y Raja Rampersaud, Jeremy Reynolds, Dean Chou, Chetan Bettegowda, Ehud Mendel, Michael H Weber, Daniel M Sciubba
STUDY DESIGN: Systematic review. OBJECTIVE: Surgical decompression and reconstruction of symptomatic spinal metastases has improved the quality of life in cancer patients. However, most data has been collected on cohorts of patients with mixed tumor histopathology. We systematically reviewed the literature for prognostic factors specific to the surgical treatment of prostate metastases to the spine. METHODS: A systemic review of the literature was conducted to answer the following questions: Question 1...
August 2017: Global Spine Journal
https://www.readbyqxmd.com/read/28811771/predictive-value-of-stathmin-1-and-osteopontin-expression-for-taxan-resistance-in-metastatic-castrate-resistant-prostate-cancer
#7
Asude Aksoy, Gokhan Artas, Omur Gokmen Sevindik
OBJECTIVE: Several pathways are known to be activated during metastasis and treatment of cancer. We investigated the role of osteopontin (OPN) and stathmin-1 (STHMN1) in metastatic castrate-resistant (mCRPC). METHODS: We included 30 patients who received at least 6 cycles of taxane regimen for metastatic mPC in the present study. For this study retrospective data was taken from Firat University, Faculty of Medicine, Medical Oncology Department between 2009 and 2015...
May 2017: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/28811062/validation-of-the-prostate-health-index-in-a-predictive-model-of-prostate-cancer
#8
A Sanchís-Bonet, M Barrionuevo-González, A M Bajo-Chueca, L Pulido-Fonseca, L E Ortega-Polledo, J C Tamayo-Ruiz, M Sánchez-Chapado
OBJECTIVES: To validate and analyse the clinical usefulness of a predictive model of prostate cancer that incorporates the biomarker «[-2] pro prostate-specific antigen» using the prostate health index (PHI) in decision making for performing prostate biopsies. MATERIAL AND METHODS: We isolated serum from 197 men with an indication for prostate biopsy to determine the total prostate-specific antigen (tPSA), the free PSA fraction (fPSA) and the [-2] proPSA (p2PSA)...
August 12, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28808664/expression-of-telomere-repeat-binding-factor-1-and-trf2-in-prostate-cancer-and-correlation-with-clinical-parameters
#9
Wei Chen, Yong Wang, Fei Li, Wei Lin, Yong Liang, Zhiwei Ma
OBJECTIVE: The objective of this study was to investigate the expression of telomere repeat binding factor 1 (TRF1) and TRF2 in prostate cancer and their relationships with clinicopathological features. METHODS: In total 50 prostate cancer tissues and paired benign prostate hyperplasia tissues were analyzed. The telomere-binding proteins TRF1 and TRF2 were measured using immunohistochemical method. Correlation analyses were used to evaluate the association between immunohistochemical score and clinical parameters...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28808221/genetic-variation-of-the-psca-gene-rs2294008-is-not-associated-with-the-risk-of-prostate-cancer
#10
Il-Seok Lee, Sung Pil Seo, Yun Sok Ha, Pildu Jeong, Ho Won Kang, Won Tae Kim, Yong-June Kim, Seok Joong Yun, Sang Cheol Lee, Wun-Jae Kim
Prostate stem cell antigen (PSCA) is a cell-membrane glycoprotein consisting of 123 amino acids and highly expressed in the prostate, but there have been few reports on the relationship between rs2294008 ofPSCA and prostate cancer in the literature. Therefore, we evaluated the association between rs2294008 and the risk of prostate cancer. A total of 240 prostate cancer patients and 306 controls (patients with benign prostatic hyperplasia) were enrolled. Genotype analysis of rs2294008 ofPSCA was performed using PCR...
January 19, 2017: Journal of Biomedical Research
https://www.readbyqxmd.com/read/28807747/pretreatment-3t-multiparametric-mri-staging-predicts-for-biochemical-failure-in-high-risk-prostate-cancer-treated-with-combination-high-dose-rate-brachytherapy-and-external-beam-radiotherapy
#11
John V Hegde, D Jeffrey Demanes, Darlene Veruttipong, Jagdeep Raince, Sang-June Park, Steven S Raman, Nicholas G Nickols, Christopher R King, Amar U Kishan, Michael L Steinberg, Mitchell Kamrava
PURPOSE: To determine whether pretreatment 3T multiparametric MRI (mpMRI) staging impacts biochemical recurrence-free survival (BRFS) or distant metastasis-free survival (DMFS) for men with high-risk prostate cancer treated with combination high-dose-rate (HDR) brachytherapy and external beam radiation therapy (EBRT). MATERIALS AND METHODS: This institutional review board-approved retrospective study included a cohort of 37 men with high-risk prostate cancer treated with HDR brachytherapy and EBRT after 3T mpMRI...
August 11, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28807532/multicenter-evaluation-of-biochemical-relapse-free-survival-outcomes-for-intraoperatively-planned-prostate-brachytherapy-using-an-automated-delivery-system
#12
Kevin Martell, Siraj Husain, Daniel Taussky, Steve Angyalfi, Guila Delouya, Philippe Després, Luc Beaulieu, Andre-Guy Martin, Eric Vigneault
PURPOSE: To report biochemical recurrence in prostate cancer treated with intraoperatively planned low-dose-rate prostate brachytherapy using an automated delivery system (IO-LDRB). METHODS AND MATERIALS: Between 2003 and 2013, 2608 patients from 3 centers were treated with IO-LDRB as single-modality treatment for low or low-tier intermediate-risk prostate cancer. Databases from the 3 centers have been analyzed. These independent databases were collected prospectively...
June 6, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28806322/reduced-field-of-view-diffusion-weighted-magnetic-resonance-imaging-of-the-prostate-at-3-tesla-comparison-with-standard-echo-planar-imaging-technique-for-image-quality-and-tumor-assessment
#13
Tsutomu Tamada, Justin M Ream, Ankur M Doshi, Samir S Taneja, Andrew B Rosenkrantz
OBJECTIVE: The purpose of this study was to compare image quality and tumor assessment at prostate magnetic resonance imaging (MRI) between reduced field-of-view diffusion-weighted imaging (rFOV-DWI) and standard DWI (st-DWI). METHODS: A total of 49 patients undergoing prostate MRI and MRI/ultrasound fusion-targeted biopsy were included. Examinations included st-DWI (field of view [FOV], 200 × 200 mm) and rFOV-DWI (FOV, 140 × 64 mm) using a 2-dimensional (2D) spatially-selective radiofrequency pulse and parallel transmission...
August 12, 2017: Journal of Computer Assisted Tomography
https://www.readbyqxmd.com/read/28806263/18f-dcfbc-prostate-specific-membrane-antigen-targeted-pet-ct-imaging-in-localized-prostate-cancer-correlation-with-multiparametric-mri-and-histopathology
#14
Baris Turkbey, Esther Mena, Liza Lindenberg, Stephen Adler, Sandra Bednarova, Rose Berman, Anita T Ton, Yolanda McKinney, Philip Eclarinal, Craig Hill, George Afari, Sibaprasad Bhattacharyya, Ronnie C Mease, Maria J Merino, Paula M Jacobs, Bradford J Wood, Peter A Pinto, Martin G Pomper, Peter L Choyke
PURPOSE: To assess the ability of (N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-F-fluorobenzyl-L-cysteine) (F-DCFBC), a prostate-specific membrane antigen-targeted PET agent, to detect localized prostate cancer lesions in correlation with multiparametric MRI (mpMRI) and histopathology. METHODS: This Health Insurance Portability and Accountability Act of 1996-compliant, prospective, institutional review board-approved study included 13 evaluable patients with localized prostate cancer (median age, 62...
August 12, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28806117/postdiagnosis-statin-use-and-mortality-in-danish-patients-with-prostate-cancer
#15
Signe Benzon Larsen, Christian Dehlendorff, Charlotte Skriver, Susanne Oksbjerg Dalton, Christina Gade Jespersen, Michael Borre, Klaus Brasso, Mette Nørgaard, Christoffer Johansen, Henrik Toft Sørensen, Jesper Hallas, Søren Friis
Purpose Increasing evidence indicates that statin use may reduce mortality from prostate cancer. In this work, we examined whether postdiagnosis statin use was associated with reduced cancer-specific mortality or all-cause mortality among patients with prostate cancer in Denmark. Material and Methods From nationwide Danish registries, we identified all patients with incident prostate adenocarcinoma from 1998 to 2011 and retrieved data on tumor and patient characteristics, drug use, and primary treatment. We defined postdiagnosis use (two or more prescriptions) of statins as a time-varying covariate with 1-year lag...
August 14, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28804579/validity-of-prostate-health-index-and-percentage-of-2-pro-prostate-specific-antigen-as-novel-biomarkers-in-the-diagnosis-of-prostate-cancer-omani-tertiary-hospitals-experience
#16
Safana S Al Saidi, Nafila B Al Riyami, Mohammed S Al Marhoon, Mohammed S Al Saraf, Salim S Al Busaidi, Riad Bayoumi, Waad-Allah S Mula-Abed
OBJECTIVES: Prostate cancer is the leading cancer in older men. The Ministry of Health Oman Cancer Incidence Registry 2013 lists cancer of the prostate as the first most common cancer in males. Therefore, early detection is important and prostate-specific antigen (PSA) is widely used as an established laboratory test. However, despite its wide use, its value in screening, particularly in asymptomatic males, is controversial when considering the risks and benefits of early detection. METHODS: This prospective, observational study included 136 males (67...
July 2017: Oman Medical Journal
https://www.readbyqxmd.com/read/28801885/active-surveillance-for-intermediate-risk-prostate-cancer
#17
REVIEW
Laurence Klotz
PURPOSE OF REVIEW: Active surveillance is now widely utilized for the management of low-risk prostate cancer (PCa). The limits of surveillance for men with intermediate risk cancer are controversial. While there is a broad consensus that men with low-risk disease can be safely managed with AS, many potential candidates, including those with Gleason 3 + 4 disease, PSA >10, younger men and African-Americans are often excluded. RECENT FINDINGS: Outcome data for intermediate-risk patients managed by active surveillance demonstrate reasonable outcomes, but these men clearly are at higher risk for progression to metastatic disease...
August 11, 2017: Current Urology Reports
https://www.readbyqxmd.com/read/28801241/trends-in-radical-prostatectomy-risk-group-distribution-in-a-european-multicenter-analysis-of-28-572-patients-towards-tailored-treatment
#18
Roderick van den Bergh, Giorgio Gandaglia, Derya Tilki, Hendrik Borgmann, Piet Ost, Christian Surcel, Massimo Valerio, Prasanna Sooriakumaran, Alberto Briganti, Markus Graefen, Henk van der Poel, Alexandre de la Taille, Francesco Montorsi, Guillaume Ploussard
BACKGROUND: Active surveillance (AS) has been increasingly proposed as the preferential initial management strategy for low-risk prostate cancer (PC), while in high-risk PC the indication for surgery has widened. OBJECTIVE: To evaluate the development of risk group distribution of patients undergoing radical prostatectomy (RP). DESIGN, SETTING, AND PARTICIPANTS: Retrospective database review of combined RP databases (2000-2015) of four large European centers (Créteil, Paris; San Rafaele, Milan; Martini Klinik, Hamburg; NKI, AvL, Amsterdam)...
August 8, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28801025/toward-an-mri-based-nomogram-for-the-prediction-of-transperineal-prostate-biopsy-outcome-a-physician-and-patient-decision-tool
#19
Su-Min Lee, Sidath H Liyanage, Wahyu Wulaningsih, Konrad Wolfe, Thomas Carr, Choudhry Younis, Mieke Van Hemelrijck, Rick Popert, Peter Acher
PURPOSE: To develop and internally validate a nomogram using biparametric magnetic resonance imaging (B-MRI)-derived variables for the prediction of prostate cancer at transperineal sector-guided prostate biopsy (TPSB). SUBJECTS/PATIENTS AND METHODS: Consecutive patients referred to our institution with raised prostate-specific antigen (PSA), abnormal prostate examination, or persistent suspicion of prostate cancer after previous transrectal biopsy between July 2012 and November 2015 were reviewed from a prospective database...
August 8, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28800492/adding-abiraterone-to-androgen-deprivation-therapy-in-men-with-metastatic-hormone-sensitive-prostate-cancer-a%C3%A2-systematic-review-and-meta-analysis
#20
Larysa H M Rydzewska, Sarah Burdett, Claire L Vale, Noel W Clarke, Karim Fizazi, Thian Kheoh, Malcolm D Mason, Branko Miladinovic, Nicholas D James, Mahesh K B Parmar, Melissa R Spears, Christopher J Sweeney, Matthew R Sydes, NamPhuong Tran, Jayne F Tierney
BACKGROUND: There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer (mHSPC). This systematic review aims to assess the effects of adding abiraterone acetate plus prednisone/prednisolone (AAP) to ADT. METHODS: Using our framework for adaptive meta-analysis (FAME), we started the review process before trials had been reported and worked collaboratively with trial investigators to anticipate when eligible trial results would emerge...
August 8, 2017: European Journal of Cancer
keyword
keyword
106912
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"